More recent chemotherapeutics include taxols and the anti-epidermal growth factor receptor (anti-EGFR) antibody cetuximab, which, despite having been specifically approved for recurrent and metastatic HNC, has also been associated with an improvement in response rates and increased survival in locoregional HNSCC [15,16]. Here, EGFR is linked to head and neck squamous cell carcinoma.